almb-0168
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2021 (NCT04886765)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06416358 | Phase 2 | May 31, 2024 | AlaMab Therapeutics (Shanghai) Inc., Sun Yat-Sen University |
| NCT04886765 | Phase 1/Phase 2 (Phase 2) | May 31, 2021 | AlaMab Therapeutics (Shanghai) Inc., Shijiazhuang Pharma Group (CSPC), Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AlaMab Therapeutics (Shanghai) Inc. | For profit | 2 | 2 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1